loading
Viking Therapeutics Inc stock is traded at $25.65, with a volume of 1.97M. It is down -1.84% in the last 24 hours and down -10.53% over the past month.
See More
Previous Close:
$26.13
Open:
$25.98
24h Volume:
1.97M
Relative Volume:
0.48
Market Cap:
$3.29B
Revenue:
-
Net Income/Loss:
$-99.15M
P/E Ratio:
-27.58
EPS:
-0.93
Net Cash Flow:
$-74.25M
1W Performance:
-11.40%
1M Performance:
-10.53%
6M Performance:
-58.38%
1Y Performance:
-68.72%
1-Day Range:
Value
$25.21
$26.23
1-Week Range:
Value
$25.21
$29.60
52-Week Range:
Value
$24.44
$82.00

Viking Therapeutics Inc Stock (VKTX) Company Profile

Name
Name
Viking Therapeutics Inc
Name
Phone
858-704-4660
Name
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Name
Employee
0
Name
Twitter
@viking_vktx
Name
Next Earnings Date
2024-10-23
Name
Latest SEC Filings
Name
VKTX's Discussions on Twitter

Compare VKTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VKTX
Viking Therapeutics Inc
25.65 3.29B 0 -99.15M -74.25M -0.93
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-13-25 Initiated Scotiabank Sector Outperform
Feb-07-25 Initiated Citigroup Neutral
Dec-02-24 Initiated Piper Sandler Overweight
Nov-22-24 Initiated B. Riley Securities Buy
Nov-04-24 Reiterated H.C. Wainwright Buy
Sep-11-24 Initiated JP Morgan Overweight
Jun-27-24 Initiated Morgan Stanley Overweight
May-16-24 Upgrade Raymond James Outperform → Strong Buy
Mar-26-24 Reiterated Oppenheimer Outperform
Mar-07-24 Initiated Jefferies Buy
Feb-28-24 Reiterated Oppenheimer Outperform
May-31-23 Resumed ROTH MKM Buy
Mar-28-23 Reiterated Maxim Group Buy
Mar-17-23 Initiated Stifel Buy
Jul-29-21 Resumed BTIG Research Buy
May-25-21 Downgrade Raymond James Strong Buy → Outperform
Jun-05-20 Initiated BMO Capital Markets Outperform
May-05-20 Initiated Chardan Capital Markets Buy
May-01-20 Initiated BTIG Research Buy
Jul-16-19 Initiated Oppenheimer Outperform
Jun-25-19 Initiated Stifel Buy
Mar-29-19 Upgrade SVB Leerink Mkt Perform → Outperform
Mar-14-19 Reiterated Maxim Group Buy
Feb-22-19 Initiated SVB Leerink Mkt Perform
Dec-12-18 Initiated B. Riley FBR Buy
Nov-19-18 Upgrade Raymond James Outperform → Strong Buy
Sep-18-18 Reiterated H.C. Wainwright Buy
Sep-18-18 Reiterated Maxim Group Buy
Sep-18-18 Reiterated Raymond James Outperform
Jul-20-18 Initiated SunTrust Buy
Jun-28-18 Initiated Raymond James Outperform
Jun-01-18 Reiterated Laidlaw Buy
May-31-18 Reiterated Maxim Group Buy
Mar-26-18 Resumed H.C. Wainwright Buy
Nov-28-17 Reiterated Maxim Group Buy
Nov-21-17 Initiated ROTH Capital Buy
View All

Viking Therapeutics Inc Stock (VKTX) Latest News

pulisher
Mar 28, 2025

A Closer Look at Viking Therapeutics's Options Market Dynamics - Benzinga

Mar 28, 2025
pulisher
Mar 27, 2025

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug - Yahoo Finance

Mar 27, 2025
pulisher
Mar 26, 2025

Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill Study - Investor's Business Daily

Mar 26, 2025
pulisher
Mar 26, 2025

Health Care Down as Viking Slides -- Health Care Roundup - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Viking Therapeutics Completes Enrollment for Phase 2 Trial of Oral Obesity Tablet - Patient Care Online

Mar 26, 2025
pulisher
Mar 26, 2025

Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Major Milestone: Viking's Oral Weight Loss Drug Advances with 280-Patient Phase 2 Trial - StockTitan

Mar 26, 2025
pulisher
Mar 25, 2025

Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly - MSN

Mar 25, 2025
pulisher
Mar 24, 2025

Viking Therapeutics, Inc. (VKTX) Rises But Trails Market: What Investors Should Know - MSN

Mar 24, 2025
pulisher
Mar 24, 2025

(VKTX) Investment Analysis - Stock Traders Daily

Mar 24, 2025
pulisher
Mar 21, 2025

Market Whales and Their Recent Bets on VKTX Options - Benzinga

Mar 21, 2025
pulisher
Mar 20, 2025

1 Biotech Stock Down 52% That Could Soar by 233%, According to Wall Street - Yahoo Finance

Mar 20, 2025
pulisher
Mar 19, 2025

Down 65% From Its 52-Week High, Is Viking Therapeutics Stock a Bargain Buy? - Yahoo

Mar 19, 2025
pulisher
Mar 18, 2025

Why Novo Nordisk Stock Outpaced the Market on Tuesday - The Motley Fool

Mar 18, 2025
pulisher
Mar 18, 2025

Is Viking Therapeutics the Next Blockbuster GLP-1 Stock? - MarketBeat

Mar 18, 2025
pulisher
Mar 17, 2025

Viking Therapeutics (NasdaqCM:VKTX) Soars 10% With CordenPharma Manufacturing Agreement - Yahoo Finance

Mar 17, 2025
pulisher
Mar 16, 2025

Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug - MSN

Mar 16, 2025
pulisher
Mar 15, 2025

Viking Therapeutics Just Inked A $150 Million Manufacturing Deal. Here's Why Shares Crumbled. - MSN

Mar 15, 2025
pulisher
Mar 14, 2025

Health Care Down as Traders Seek Out Defensive Sectors -- Health Care Roundup -March 14, 2025 at 05:24 pm EDT - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

Why Viking Therapeutics Inc. (VKTX) Is Skyrocketing Today? - MSN

Mar 14, 2025
pulisher
Mar 13, 2025

Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note - MSN

Mar 13, 2025
pulisher
Mar 13, 2025

Viking Therapeutics: No Buyout Needed Now (NASDAQ:VKTX) - Seeking Alpha

Mar 13, 2025
pulisher
Mar 13, 2025

(VKTX) Long Term Investment Analysis - Stock Traders Daily

Mar 13, 2025
pulisher
Mar 13, 2025

How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma - Zacks Investment Research

Mar 13, 2025
pulisher
Mar 13, 2025

Viking Therapeutics (NASDAQ:VKTX) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

10 Stocks Skyrocketing Today - Insider Monkey

Mar 12, 2025
pulisher
Mar 12, 2025

Why VKTX Stock is Moving Today - GuruFocus.com

Mar 12, 2025
pulisher
Mar 12, 2025

Viking Therapeutics Secures Manufacturing Agreement with CordenPharma, Boosting Growth Prospects and Investor Appeal - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped - Yahoo

Mar 12, 2025
pulisher
Mar 12, 2025

Viking Therapeutics’ new contract is a game changer. Here’s how much money it could bring in. - MarketWatch

Mar 12, 2025
pulisher
Mar 12, 2025

Behind the Scenes of Viking Therapeutics's Latest Options Trends - Benzinga

Mar 12, 2025
pulisher
Mar 12, 2025

B. Riley sees two key positives in Viking manufacturing agreement - Yahoo Finance

Mar 12, 2025
pulisher
Mar 12, 2025

Viking Therapeutics call volume above normal and directionally bullish - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Viking shares slip after manufacturing deal announced - The Pharma Letter

Mar 12, 2025
pulisher
Mar 12, 2025

VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug Supply - Yahoo Finance

Mar 12, 2025
pulisher
Mar 12, 2025

Viking Therapeutics Is Ready For A Standalone Future (NASDAQ:VKTX) - Seeking Alpha

Mar 12, 2025
pulisher
Mar 12, 2025

Viking Therapeutics Secures Strategic Manufacturing Agreement with CordenPharma, Boosting Growth Potential and Earning Buy Rating - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Viking Therapeutics Secures Strategic Manufacturing Agreement, Boosting Investor Confidence and Phase 3 Trial Prospects - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Bank of New York Mellon Corp Grows Position in Viking Therapeutics, Inc. (NASDAQ:VKTX) - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

CordenPharma and Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables and Oral Formulations - Barchart

Mar 11, 2025
pulisher
Mar 11, 2025

Health Care Down on Flight From Biotech, Obesity Drug Makers -- Health Care Roundup - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735 - The Malaysian Reserve

Mar 11, 2025
pulisher
Mar 11, 2025

Viking Therapeutics: Finally, Here Comes The Buying Opportunity (Upgrade) - Seeking Alpha

Mar 11, 2025
pulisher
Mar 11, 2025

Stellantis, Tesla, Viking Therapeutics: Market Minute - Yahoo Finance

Mar 11, 2025
pulisher
Mar 11, 2025

Viking Therapeutics closer to bringing its Ozempic competitor to market - Yahoo Finance

Mar 11, 2025
pulisher
Mar 11, 2025

Viking Therapeutics Shares Fall After Manufacturing Deal With CordenPharma -March 11, 2025 at 11:08 am EDT - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy? - MSN

Mar 11, 2025
pulisher
Mar 11, 2025

Strategic Manufacturing Deal Boosts Viking Therapeutics’ Stock Outlook - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Viking Therapeutics Signs Broad Manufacturing Agreement with CordenPharma - Contract Pharma

Mar 11, 2025
pulisher
Mar 11, 2025

Cordenpharma, Viking Therapeutics form long-term partnership to provide key materials to make injectable and oral medications - Marketscreener.com

Mar 11, 2025

Viking Therapeutics Inc Stock (VKTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Viking Therapeutics Inc Stock (VKTX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Mancini Marianna
Chief Operating Officer
Jan 06 '25
Sale
42.75
54,215
2,317,599
374,134
ZANTE GREG
Chief Financial Officer
Jan 06 '25
Sale
42.75
50,309
2,150,595
165,259
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
Cap:     |  Volume (24h):